U.S. Markets close in 5 hrs 56 mins


. Currency in USD
Add to watchlist
Full screen
Previous CloseN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
Avg. VolumeN/A
Market CapN/A
PE Ratio (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • 3 High-Yield Pharmaceutical Stocks
    Motley Fool4 hours ago

    3 High-Yield Pharmaceutical Stocks

    Pfizer, GlaxoSmithKline, and Novo Nordisk all offer up temptingly high yields. Here's why they're worth putting on your radar.

  • 3 High-Yield Stocks to Own in a Market Crash
    Motley Fool18 hours ago

    3 High-Yield Stocks to Own in a Market Crash

    If you're concerned about a forthcoming market correction, GlaxoSmithKline, AT&T, and Procter & Gamble may be worth buying right now.

  • Barrons.com21 hours ago

    UPDATE: Shire: There Goes the CFO!

    Update: I spoke with Shire (SHPG) CFO Jeff Poulton about his decision to leave, and he was quick to dispel any concerns that his departure was about anything except his desire to pursue a new opportunity. Poulton also said that calling Shire a specialty-pharmaceutical company is a misnomer, as an overwhelming percentage of revenue now comes from its orphan drug business, a point raised by analyst Evercore ISI analyst Josh Schimmer, who wrote that Shire has "biotech cash flows with a spec pharma valuation" in a note last week. Shares of Shire have fallen 4% to $139.71 at 1:26 p.m. today.